Absci 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- For the 3 months ended September 30th, 2026, research and development expenses were $23.6 million, compared with $19.2 million in the prior year period, primarily reflecting increased costs for internal programs, including ABS-201 development, partially offset by lower personnel-related costs.
- Selling, general, and administrative expenses were $9 million, compared with $8.4 million in the prior year period, primarily due to stock-based compensation.
- Cash, cash equivalents, and marketable securities were $173.7 million as of September 30th, 2026, compared with $201.1 million as of June 30th, 2026.
- ABS-201’s Phase 1/2a headline trial in pattern hair loss continued to enroll and progress according to plan; management reported that enrollment in the highest-dose cohort was complete.
- The trial is randomized, double-blind, and placebo-controlled, with safety and tolerability as primary endpoints and PK/PD, immunogenicity, hair measures, and patient-reported outcomes among the secondary endpoints.
- Absci began enrolling two exploratory, open-label female pattern hair loss cohorts at doses of 300 milligrams and 1,200 milligrams.
- Absci plans a global, dose-ranging Phase 2 STORILINE trial of ABS-201 in endometriosis, designed to assess efficacy and safety in approximately 150 patients across approximately 10 or more countries, subject to protocol finalization and regulatory clearance.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good day, and thank you for standing by. Welcome to the Absci Q3 2026 business update and financial and operating results conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during the session, you will need to press star one one on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star one one again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today, Alex Khan, Investor Relations. Please go ahead. Thank you.
Earlier today, Absci released financial and operating results for the quarter ended September 30, 2026. If you haven't received this news release, or if you'd like to be added to the company's distribution list, please send an email to investors@absci.com. An archived webcast of this call will be available for replay on Absci's investor relations website at investors.absci.com for at least 90 days after this call. Joining me today are Sean McClain, Absci's founder and CEO, Zach Jonasson, Chief Financial Officer and Chief Business Officer, and Ransi Somaratne, Chief Medical Officer, Head of R&D. Before we begin, I'd like to remind you that management will make statements during this call that are forward-looking within the meaning of the federal securities laws.
These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated, and you should not place undue reliance on forward-looking statements. These statements involve forward-looking statements regarding ABS-201 and our other pipeline programs, including the conduct and timing of our phase I/IIa HEADLINE trial in pattern hair loss, with an interim proof of concept data expected in December 2026 and full proof of concept data in early 2027, potential advance into phase III, including an expedited path directly from phase I/IIa, a planned phase II endometriosis trial starting in mid-2027, ABS-201's anticipated product profile and target product profile, planned FDA engagement on development strategy, ABS-201's market opportunity and commercial prospects, and the capabilities and benefits of our platform technologies.
Market projections rely on assumptions, including regulatory approval, the final label, and the competitive landscape, any of which could cause the actual addressable market to differ materially. Certain research findings discussed today reflect participant responses to a hypothetical product profile and are not clinical results for ABS-201. Additional information regarding the risks and uncertainties that could affect our forward-looking statements is set forth in the press release Absci issued today and our most recent annual report on Form 10-K and subsequent documents or reports filed by Absci from time to time with the SEC. Except as required by law, Absci disclaims any intention or obligation to update or revise any financial or product pipeline projections or other forward-looking statements, either because of new information, future events, or otherwise. This conference call contains time-sensitive information and is accurate only as of the live broadcast, November 12, 2026.
With that, I'll turn the call over to Sean.
Thanks, Alex. Good morning, everyone. Thanks for joining us. Absci continues to make strides across our whole business. Today, we'll walk you through the exciting developments we're looking forward to, including our upcoming 13-week interim POC data in pattern hair loss next month, the full POC data in pattern hair loss early next year, our planned endometriosis phase II clinical trial, and the expansive potential we see with our prolactin franchise. I'm pleased to share that the HEADLINE trial has been progressing according to plan. We're continuing to enroll and execute the trial towards near-term proof of concept data. Ronny will discuss this later in the call. Next month, we anticipate sharing interim 13-week data. The dataset could demonstrate early signs of regenerative prolactin mechanism, stimulating and promoting hair growth. We are incredibly excited to be gathering and sharing these data with you all very soon.
As we mentioned in September, we're also excited to be moving toward initiation of our planned phase II clinical trial in endometriosis. This disease has been severely overlooked and underinvested in for far too long. Our STORYLINE trial is being designed to measure pain-related outcomes. We also believe that the prolactin mechanism has the potential to be disease-modifying based on prolactin's described role in endometrial tissue proliferation and lesion growth. In that sense, the prolactin mechanism for endometriosis could represent a novel treatment for women suffering from this painful and burdensome disease. While we remain laser-focused on executing our HEADLINE and upcoming STORYLINE clinical trials for ABS-201, we've also been exploring other potential indications for the prolactin receptor antibodies. These additional indications give us a path forward to further expand our prolactin franchise. Our team and our end-to-end platform have together generated novel insights into prolactin biology.
We are proud to be pioneers and leaders in this space. Our aim is to harness this biology for betterment of human health across various disease and lifestyle areas. Our early-stage pipeline, also including non-prolactin targets, is being developed for indications within metabolism, I&I, healthy aging, preventative care, and lifestyle optimization. Most or all of these would be developed with a direct-to-consumer focus. I'm also thrilled to be welcoming Gerry Muhle to Absci as our first Chief Commercial Officer. We're continuing to advance ABS-201 through the clinic and build out our franchise of potential direct-to-consumer programs. Gerry's wealth of experience in pharma, aesthetics, and consumer products makes him uniquely suited for this role. I'm excited to be working with him as we build out our infrastructure to support the potential commercial future of Absci.
ABS-201 is the blueprint, a novel mechanism for a large patient population with high unmet medical need. Our platform and business strategy are made for this, and the assets which stem from the platform are the results as well. We'll have a first look at the results very soon. Our interim 13-week PHL data is anticipated next month. Then early next year, we anticipate our full 26-week data. With that, I'll turn it over to Ranzi to walk through ABS-201 clinical program.
Ranzi? Thanks, Sean, and good morning, everyone.
I am pleased to say that the ongoing HEADLINE trial continues to enroll and progress according to plan. We continue to be encouraged by the emerging safety, pharmacokinetic, and immunogenicity profile observed to date. As we said in June, blinded aggregate interim data suggested study drug was well tolerated and exhibited a favorable safety and tolerability profile. Additionally, the estimated half-life, based on available interim pharmacokinetic data across all four SAD cohorts, supports the potential to achieve ABS-201's targeted dosing regimen of two or three injections over a six-month period. As Sean mentioned, we are very excited to be sharing our interim 13-week PHL data with you all next month. We also continue to anticipate our full 26-week proof of concept data early next year. As a reminder, our ongoing HEADLINE trial is a randomized, double-blind, placebo-controlled study.
The primary endpoints for the study are safety and tolerability. Secondary endpoints include PK, PD, immunogenicity, target area hair count, target area hair width, and target area darkening pigmentation. We will also be collecting patient-reported outcomes data from this study. At the early time point, the 13-week interim POC data we anticipate sharing next month, we plan to report male pattern hair loss data, including target area hair count, or TAHC, which counts the non-vellus hairs, which are 30 microns or greater, target area hair width, as well as total hairs, a measure that also includes vellus hairs in addition to non-vellus. As the prolactin receptor mechanism represents novel biology for hair regrowth, we believe examining only the conventional metrics of hair growth studies, like non-vellus hairs, wouldn't tell us the full story. We believe ABS-201's mechanism of action would support growth in active and potentially in dormant follicles.
Though we're also interested in looking at the total hair count, which includes vellus hairs that we believe may have the potential to convert to non-vellus hairs at a later time point. Taken together, we believe the 13-week interim POC data we plan to share next month could show a strong directional signal of biological activity, which could lead to even more robust hair growth at the 26-week time point and beyond. We've also begun enrollment of two cohorts of female participants with PHL at doses of 1,200 milligrams and 300 milligrams. We will share additional details about these female cohorts and timing for data at a later date. As Sean mentioned earlier, we are excited by the advances we have made for our ABS-201 program in endometriosis. In September, we announced additional details for our planned global, multicenter phase II STORYLINE clinical trial.
This phase II double-blind, randomized placebo-controlled trial would assess efficacy and safety in participants with surgically diagnosed endometriosis and moderate to severe endometriosis-associated pain after a two-cycle run-in period. Efficacy endpoints for the trial would include reductions in dysmenorrhea and non-menstrual pelvic pain, as reported via patient-reported measures. We anticipate recruiting approximately 150 patients from approximately 10 or more countries, subject to protocol finalization and regulatory clearance. Leveraging the safety, tolerability, and PK data being generated for ABS-201 in our ongoing HEADLINE trial, we anticipate initiation of this phase II clinical trial for endometriosis in mid-2027. We are designing STORYLINE as a dose-ranging trial and anticipate testing two or three dose levels that will be confirmed following review of HEADLINE data. Endometriosis is a disease with significant unmet medical need, and we are motivated to make strides for the millions of women suffering from this condition.
Overall, we remain focused on executing our ABS-201 program for both pattern hair loss and endometriosis, and look forward to sharing our 13-week interim PHL data with you all next month. With that, I'll pass it over to Zach to discuss our business strategy and to provide an update on our financials.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
15 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
